Amylyx Pharmaceuticals (AMLX) EBIT Margin: 2021-2024
Historic EBIT Margin for Amylyx Pharmaceuticals (AMLX) over the last 2 years, with Dec 2024 value amounting to -155.00%.
- Amylyx Pharmaceuticals' EBIT Margin fell 15652.00% to -155.00% in Q4 2024 from the same period last year, while for Dec 2024 it was -270.59%, marking a year-over-year decrease of 27959.00%. This contributed to the annual value of -275.44% for FY2024, which is 28443.00% down from last year.
- Amylyx Pharmaceuticals' EBIT Margin amounted to -155.00% in Q4 2024, which was up 99.15% from -18,187.74% recorded in Q3 2024.
- In the past 5 years, Amylyx Pharmaceuticals' EBIT Margin ranged from a high of 18.63% in Q2 2023 and a low of -18,187.74% during Q3 2024.
- Its 3-year average for EBIT Margin is -3,606.76%, with a median of -146.39% in 2024.
- Its EBIT Margin has fluctuated over the past 5 years, first spiked by 1,001,326bps in 2023, then crashed by 1,820,447bps in 2024.
- Amylyx Pharmaceuticals' EBIT Margin (Quarterly) stood at -8,041.40% in 2021, then plummeted by 195,512bps to -167.91% in 2022, then surged by 16,944bps to 1.53% in 2023, then tumbled by 15,652bps to -155.00% in 2024.
- Its EBIT Margin stands at -155.00% for Q4 2024, versus -18,187.74% for Q3 2024 and -7,457.09% for Q2 2024.